NEW YORK, May 5 (GenomeWeb News) – Cepheid announced yesterday that its Q1 revenues increased 3 percent to $20.2 million from $19.6 million during the year-ago period, while its net loss grew 9.3 percent to $6.7 million from $3.5 million during the first quarter of 2005. Research and development costs grew 2.9 percent to $5.8 million from $4.5 million during the first quarter of 2005. As of March 31, Cepheid had $59.7 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.